Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Clinical trial NCT07374029 · RECRUITING
Trial details
- NCT number
- NCT07374029
- Sponsor
- David Avigan
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-12
- Primary completion
- 2027-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.